Bausch Health Companies Inc. (TSE:BHC - Free Report) - Investment analysts at Zacks Research lifted their Q2 2025 earnings estimates for shares of Bausch Health Companies in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.52 for the quarter, up from their prior forecast of $1.49. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2025 earnings at $1.67 EPS, Q1 2026 earnings at $1.59 EPS, Q4 2026 earnings at $1.80 EPS, FY2026 earnings at $6.84 EPS and FY2027 earnings at $8.21 EPS.
Bausch Health Companies Price Performance
BHC traded down C$0.22 during trading on Thursday, reaching C$10.05. The company's stock had a trading volume of 239,121 shares, compared to its average volume of 291,021. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of -1,831.94. The firm has a fifty day simple moving average of C$10.37 and a two-hundred day simple moving average of C$10.63. Bausch Health Companies has a 1 year low of C$5.45 and a 1 year high of C$15.43. The company has a market cap of C$2.61 billion, a price-to-earnings ratio of -14.71, a PEG ratio of 0.21 and a beta of 0.77.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Recommended Stories
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
